Exonhit receives financial support from OSEO
At the beginning of the project during the first semester of 2012, an amount of €1,126,000 was paid to Exonhit. The consortium aims at developing new therapies for
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
According to the agreement, the companies will investigate the next generation of the Biological Nano Particles, Chatham’s recombinant adeno-associated virus-based gene therapy technology, through US-based hemophilia B clinical